<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>There is much biochemical evidence, but very few studies in animal models of <z:hpo ids='HP_0001297'>stroke</z:hpo> in vivo, to suggest that Ginkgo biloba (EGb 761) may offer neuroprotection against regional, ischemic brain damage; additional investigations are needed to ensure future clinical trials </plain></SENT>
<SENT sid="1" pm="."><plain>This study reports the effects of EGb 761 given acutely or chronically before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Rats were subjected to middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) for 2 h and the brain <z:mpath ids='MPATH_124'>infarct</z:mpath> size was assessed 24 h later </plain></SENT>
<SENT sid="3" pm="."><plain>Dipyrone (100 mg/kg, i.p.) was injected 30 min before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, and 2.5 and 5.5 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, to reduce <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced <z:hpo ids='HP_0001945'>fever</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>EGb 761 (Tebonin) was given acutely (200 mg/kg, p.o., 60 min before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>) or chronically (100 mg/kg, p.o., once daily, for 14 days before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> or <z:hpo ids='HP_0011010'>chronic</z:hpo> treatment with EGb 761, either alone or in combination with dipyrone, did not reduce the <z:mpath ids='MPATH_124'>infarct</z:mpath> size compared with saline alone (p &gt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>Dipyrone failed to prevent <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced <z:hpo ids='HP_0001945'>fever</z:hpo> during the intra-ischemic period (p &gt; 0.05 vs saline; p &lt; 0.001 vs sham) </plain></SENT>
<SENT sid="7" pm="."><plain>In the reperfusion phase, dipyrone reduced <z:hpo ids='HP_0001945'>fever</z:hpo> to normothermic levels in the group treated acutely with EGb 761 (p &lt; 0.01 vs saline, p &gt; 0.05 vs sham) but not after <z:hpo ids='HP_0011010'>chronic</z:hpo> EGb 761 (p &lt; 0.01 vs sham), indicating possible pharmacokinetic interaction </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, within the context of unprevented, <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced <z:hpo ids='HP_0001945'>fever</z:hpo>, the present results demonstrate that EGb 761 has no significant effect on brain <z:mpath ids='MPATH_124'>infarct</z:mpath> size </plain></SENT>
</text></document>